Artia Global Partners
Latest statistics and disclosures from Artia Global Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, INSM, TRVI, BTSG, RVMD, and represent 44.97% of Artia Global Partners's stock portfolio.
- Added to shares of these 10 stocks: BTSG (+$32M), ALKS (+$24M), XBI (+$16M), TVTX (+$15M), RVMD (+$11M), GH (+$5.7M), ABSI (+$5.4M), DGX (+$5.2M), ASND, CYTK.
- Started 8 new stock positions in SYRE, ABSI, ALKS, ASND, CMPX, ORKA, XBI, GH.
- Reduced shares in these 10 stocks: LLY (-$35M), INSM (-$34M), ABVX (-$11M), MRNA (-$10M), TERN (-$5.5M), Ascendis Pharma A S, , Soleno Therapeutics, BBIO, ALMS.
- Sold out of its positions in ABBV, APGE, Ascendis Pharma A S, AVTX, BBIO, LLY, MRNA, Soleno Therapeutics, TERN.
- Artia Global Partners was a net buyer of stock by $32M.
- Artia Global Partners has $542M in assets under management (AUM), dropping by 8.50%.
- Central Index Key (CIK): 0001937964
Tip: Access up to 7 years of quarterly data
Positions held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 48 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 12.7 | $69M | -14% | 516k | 133.26 |
|
| Insmed Com Par $.01 (INSM) | 11.6 | $63M | -35% | 589k | 106.62 |
|
| Trevi Therapeutics (TRVI) | 7.6 | $41M | +9% | 2.2M | 18.65 |
|
| Brightspring Health Svcs (BTSG) | 6.7 | $36M | +861% | 517k | 69.74 |
|
| Revolution Medicines (RVMD) | 6.4 | $35M | +48% | 185k | 187.28 |
|
| Argenx Se Sponsored Adr (ARGX) | 5.1 | $28M | 30k | 927.77 |
|
|
| Alkermes SHS (ALKS) | 4.3 | $24M | NEW | 449k | 52.40 |
|
| Travere Therapeutics (TVTX) | 3.6 | $19M | +379% | 339k | 56.81 |
|
| Astrazeneca Ord (AZN) | 3.4 | $19M | +3% | 98k | 189.62 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 3.2 | $17M | 504k | 33.89 |
|
|
| Dianthus Therapeutics (DNTH) | 2.9 | $16M | 163k | 97.48 |
|
|
| Spdr Series Trust St Str Sp Biot (XBI) | 2.9 | $16M | NEW | 100k | 158.25 |
|
| Quest Diagnostics Incorporated (DGX) | 2.5 | $14M | +59% | 65k | 211.95 |
|
| Ionis Pharmaceuticals (IONS) | 2.1 | $11M | 144k | 79.29 |
|
|
| Eyepoint Com New (EYPT) | 2.0 | $11M | 767k | 14.30 |
|
|
| Alumis (ALMS) | 1.4 | $7.8M | -14% | 279k | 28.14 |
|
| Viking Therapeutics (VKTX) | 1.3 | $7.1M | 181k | 39.01 |
|
|
| Celcuity (CELC) | 1.1 | $6.2M | +280% | 59k | 104.62 |
|
| Cytokinetics Com New (CYTK) | 1.1 | $6.0M | +333% | 71k | 85.19 |
|
| Merck & Co (MRK) | 1.1 | $6.0M | 47k | 128.50 |
|
|
| Rapport Therapeutics (RAPP) | 1.1 | $5.8M | 139k | 41.67 |
|
|
| Johnson & Johnson (JNJ) | 1.1 | $5.7M | 23k | 253.97 |
|
|
| Guardant Health (GH) | 1.1 | $5.7M | NEW | 38k | 150.03 |
|
| Absci Corp (ABSI) | 1.0 | $5.4M | NEW | 464k | 11.59 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.0 | $5.3M | 96k | 55.00 |
|
|
| Sionna Therapeutics (SION) | 1.0 | $5.3M | 120k | 43.99 |
|
|
| Ascendis Pharma A/s Ord Shs (ASND) | 0.9 | $4.7M | NEW | 18k | 266.72 |
|
| Roivant Sciences SHS (ROIV) | 0.8 | $4.6M | 130k | 35.39 |
|
|
| Palisade Bio (PALI) | 0.8 | $4.2M | 2.0M | 2.09 |
|
|
| Edgewise Therapeutics (EWTX) | 0.7 | $4.0M | +50% | 99k | 40.63 |
|
| Biogen Idec (BIIB) | 0.7 | $4.0M | 18k | 216.06 |
|
|
| Xenon Pharmaceuticals (XENE) | 0.7 | $3.9M | 65k | 60.36 |
|
|
| Belite Bio Sponsored Ads (BLTE) | 0.7 | $3.8M | 25k | 153.99 |
|
|
| Mineralys Therapeutics (MLYS) | 0.7 | $3.7M | 138k | 26.98 |
|
|
| Prokidney Corp Shs Cl A (PROK) | 0.7 | $3.7M | 1.8M | 2.04 |
|
|
| Enliven Therapeutics (ELVN) | 0.7 | $3.7M | +244% | 72k | 50.75 |
|
| Oruka Therapeutics (ORKA) | 0.6 | $3.2M | NEW | 33k | 95.17 |
|
| Protagonist Therapeutics (PTGX) | 0.5 | $2.8M | 23k | 122.58 |
|
|
| United Therapeutics Corporation (UTHR) | 0.5 | $2.7M | 5.0k | 541.83 |
|
|
| Bright Minds Biosciences Com New (DRUG) | 0.5 | $2.7M | 38k | 70.20 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.3 | $1.9M | 29k | 63.95 |
|
|
| Compass Therapeutics (CMPX) | 0.2 | $839k | NEW | 383k | 2.19 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.2 | $837k | 2.5k | 334.79 |
|
|
| Kodiak Sciences (KOD) | 0.1 | $663k | 17k | 38.96 |
|
|
| Tenax Therapeutics Com New (TENX) | 0.1 | $612k | 42k | 14.55 |
|
|
| Nuvalent Inc-a (NUVL) | 0.1 | $605k | 4.9k | 123.50 |
|
|
| Pepgen (PEPG) | 0.1 | $370k | 205k | 1.80 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.1 | $355k | NEW | 4.0k | 88.78 |
|
Past Filings by Artia Global Partners
SEC 13F filings are viewable for Artia Global Partners going back to 2022
- Artia Global Partners 2026 Q2 filed Aug. 14, 2026
- Artia Global Partners 2026 Q1 filed May 15, 2026
- Artia Global Partners 2025 Q4 filed Feb. 17, 2026
- Artia Global Partners 2025 Q3 filed Nov. 14, 2025
- Artia Global Partners 2025 Q3 restated filed Nov. 14, 2025
- Artia Global Partners 2025 Q2 filed Aug. 14, 2025
- Artia Global Partners 2025 Q1 filed May 15, 2025
- Artia Global Partners 2024 Q4 filed Feb. 14, 2025
- Artia Global Partners 2024 Q3 filed Nov. 14, 2024
- Artia Global Partners 2024 Q2 filed Aug. 14, 2024
- Artia Global Partners 2024 Q1 filed May 15, 2024
- Artia Global Partners 2023 Q4 filed Feb. 14, 2024
- Artia Global Partners 2023 Q3 filed Nov. 14, 2023
- Artia Global Partners 2023 Q2 filed Aug. 14, 2023
- Artia Global Partners 2023 Q1 filed May 15, 2023
- Artia Global Partners 2022 Q4 filed Feb. 14, 2023